PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), Wednesday said that the U.S. Food and Drug Administration (FDA) has approved Ajovy for the prevention of episodic migraine in patients aged 6-17 years.
Ajovy was first approved in 2018 for the preventive treatment of migraine in adults.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News